Quoin Pharmaceuticals
QNRX
5 hedge funds and large institutions have $419K invested in Quoin Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
67% more funds holding
Funds holding: 3 → 5 (+2)
9% more capital invested
Capital invested by funds: $383K → $419K (+$36K)
0% less ownership
Funds ownership: 0% → 0% (-0%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$59.8K |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$29.9K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$22.4K |
| 4 |
HF
HRT Financial
New York
|
+$22.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$198K |
| 2 |
Renaissance Technologies
New York
|
-$44.8K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$29K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Ameriprise
Minneapolis,
Minnesota
| $256K | +$29.9K | +4 | New |
|
|
2
Renaissance Technologies
New York
| $67K | -$44.8K | -6 | -38% |
|
|
VF
3
Virtu Financial
New York
| $57K | +$59.8K | +8 | New |
|
|
HF
4
HRT Financial
New York
| $20K | +$22.4K | +3 | New |
|
|
5
Geode Capital Management
Boston,
Massachusetts
| $19K | +$22.4K | +3 | New |
|
|
6
Morgan Stanley
New York
| – | -$198K | -21 | Closed |
|
|
TSS
7
Two Sigma Securities
New York
| – | -$29K | -3 | Closed |
|
|
8
Bank of America
Charlotte,
North Carolina
| – | -$4K | – | – |
|
QNRX Hedge Fund Activity: Q1 2022 in Review
5 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Quoin Pharmaceuticals (QNRX) for Q1 2022, worth a combined $419K — up 9.4% from $383K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new QNRX positions and 2 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $59.8K. The largest seller was Morgan Stanley, exiting entirely with an estimated $198K sold.
- 5 institutional investors held Quoin Pharmaceuticals (QNRX) as of Q1 2022, up from 3 in Q4 2021.
- Funds reported $419K of Quoin Pharmaceuticals stock for Q1 2022, up 9.4% quarter-over-quarter.
- 4 funds opened new Quoin Pharmaceuticals positions in Q1 2022 and 2 closed out, a net change of +2 holders.
- The largest Quoin Pharmaceuticals buyer in Q1 2022 was Virtu Financial, an estimated $59.8K added.
- The largest Quoin Pharmaceuticals seller in Q1 2022 was Morgan Stanley, an estimated $198K sold.
Based on aggregated 13F filings for Q1 2022.